347 related articles for article (PubMed ID: 19241351)
1. The renin-angiotensin-aldosterone system: approaches to cardiac and renal therapy.
Otte M; Spier A
Compend Contin Educ Vet; 2009 Jan; 31(1):E1-7; quiz E7. PubMed ID: 19241351
[TBL] [Abstract][Full Text] [Related]
2. [Renin-angiotensin-aldosterone system (RAAS) and its pharmacologic modulation].
Giestas A; Palma I; Ramos MH
Acta Med Port; 2010; 23(4):677-88. PubMed ID: 20687997
[TBL] [Abstract][Full Text] [Related]
3. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
Weir MR; Rolfe M
Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
[TBL] [Abstract][Full Text] [Related]
4. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
Lim S
Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
[TBL] [Abstract][Full Text] [Related]
5. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease.
Brewster UC; Perazella MA
Am J Med; 2004 Feb; 116(4):263-72. PubMed ID: 14969655
[TBL] [Abstract][Full Text] [Related]
6. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
Krum H; Gilbert RE
J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
[TBL] [Abstract][Full Text] [Related]
7. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease.
Slagman MC; Navis G; Laverman GD
Curr Opin Nephrol Hypertens; 2010 Mar; 19(2):140-52. PubMed ID: 20051849
[TBL] [Abstract][Full Text] [Related]
8. [Renin inhibition and the kidney].
Ecder T
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():28-31. PubMed ID: 20019474
[TBL] [Abstract][Full Text] [Related]
9. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
Ruilope LM
Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
[TBL] [Abstract][Full Text] [Related]
10. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review.
Duprez DA
J Hypertens; 2006 Jun; 24(6):983-91. PubMed ID: 16685192
[TBL] [Abstract][Full Text] [Related]
11. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
Bomback AS; Toto R
Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
[TBL] [Abstract][Full Text] [Related]
12. The role of the renin-angiotensin-aldosterone system in cardiovascular progenitor cell function.
Qian C; Schoemaker RG; van Gilst WH; Roks AJ
Clin Sci (Lond); 2009 Feb; 116(4):301-14. PubMed ID: 19138171
[TBL] [Abstract][Full Text] [Related]
13. [Multilevel blockade of the renin-angiotensin-aldosterone system in the treatment of diabetic nephropathy].
Fronczyk A; Majkowska L
Przegl Lek; 2007; 64(2):81-5. PubMed ID: 17892038
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
Rao MS
J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
[TBL] [Abstract][Full Text] [Related]
15. The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyond.
Epstein BJ; Leonard PT; Shah NK
Expert Rev Cardiovasc Ther; 2012 Jun; 10(6):713-25. PubMed ID: 22894628
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic measures in proteinuric nephropathy.
Praga M
Kidney Int Suppl; 2005 Dec; (99):S137-41. PubMed ID: 16336567
[TBL] [Abstract][Full Text] [Related]
17. [Pathophysiological and clinical implications of AT(1)/AT(2) angiotensin II receptors in heart failure and coronary and renal failure].
Sandmann S; Unger T
Drugs; 2002; 62 Spec No 1():43-52. PubMed ID: 12036388
[TBL] [Abstract][Full Text] [Related]
18. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations.
Turgut F; Balogun RA; Abdel-Rahman EM
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1330-9. PubMed ID: 20498247
[TBL] [Abstract][Full Text] [Related]
19. Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors.
Weinberg MS; Weinberg AJ; Zappe DH
J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):217-33. PubMed ID: 11881029
[No Abstract] [Full Text] [Related]
20. Influence of renin-angiotensin-aldosterone system-blocking drugs on peritoneal membrane in peritoneal dialysis patients.
Trošt Rupnik A; Pajek J; Guček A; Osredkar J; Kovač D; Bren A; Klančič D; Saksida S; Rus I; Globokar M; Drozg A; Lešnik M; Plešivčnik Z; Ekart R; Lopert S; Lindič J
Ther Apher Dial; 2013 Aug; 17(4):425-30. PubMed ID: 23931884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
